Women with hypertension stage 1 (130-139 mmHg) at their early 40s had an increased risk of ACS during midlife, while this association was non-significant in men after adjusting for CV risk factors.
ACC 2021 Prof. Chew summarizes the 12-months follow-up findings of the rapid TnT trial comparing two protocols of hs-troponin in patients with suspected ACS. He also gives his interpretation of the results.
This registry-based cohort study showed that one-third of patients with AF and/or VTE on a DOAC received aspirin without clear therapeutic indication. Combination therapy was associated with increased bleeding rates compared to DOAC monotherapy.
A higher relative proportion of plasma long-chain omega-3 polyunsaturated fatty acids (PUFAs) was associated with lower risk of sudden cardiac death in patients after ACS.
As an author of a Clinical Review in European Heart Journal, Niels van der Sangen discusses the options for a personalized approach of antithrombotic therapy after PCI, as described in the paper.
This subanalysis of the ODYSSEY OUTCOMES trial showed that patients with recent ACS on alirocumab with achieved LDL-c <25 mg/dL had similar risk reductions for MACE as patients with LDL-c 25-50 mg/dL.
In a retrospective study, ticagrelor treatment resulted in comparable risk of net adverse clinical events (NACE) compared to clopidogrel treatment among patients from the US and South-Korea with ACS who underwent PCI.
A prespecified subanalysis of ISAR-REACT 5 demonstrated that ticagrelor and prasugrel had comparable efficacy with regard to reducing ischemic events in patients with diabetes, with a similar risk for bleeding.
A post-hoc analysis of the ODYSSEY OUTCOMES trial found that Lp(a) reduction with alirocumab was, independent of LDL-c reduction, associated with reduced total CV events in ACS patients.
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.
Malnutrition, assessed by 3 different scores, was common in a cohort of ACS patients. Malnutrition was associated with increased risk of mortality and MACE, independent of BMI.
This trial in 57 patients with non-STEMI and troponin I ≥5 ng/mL showed that more patients reach LDL-c targets at hospital discharge with evolocumab plus high-intensity statin therapy compared with placebo plus high-intensity statin therapy.